Home>>Signaling Pathways>> Others>>FAPI-46

FAPI-46

Catalog No.GC62970

FAPI-46 is a quinoline-based fibroblast activation protein (FAP)-targeted radiotracer. FAPI-46 has higher tumor uptake and prolonged tumor accumulation. FAPI-46 can be used for tumor imaging of a multitude of different cancers.

Products are for research use only. Not for human use. We do not sell to patients.

FAPI-46 Chemical Structure

Cas No.: 2374782-04-2

Size Price Stock Qty
5 mg
$810.00
In stock
10 mg
$1,485.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

FAPI-46 is a quinoline-based fibroblast activation protein (FAP)-targeted radiotracer. FAPI-46 has higher tumor uptake and prolonged tumor accumulation. FAPI-46 can be used for tumor imaging of a multitude of different cancers[1][2].

FAPI-46 (1-24 h) robustly binds to human FAP in human FAP-expressing HT-1080 cells[1].

FAPI-46 (i.v.) shows improved ratios of tumor to liver, kidney, and brain uptake, resulting in an enhanced image contrast for PET imaging[1].

[1]. Loktev A, et, al. Development of Fibroblast Activation Protein-Targeted Radiotracers with Improved Tumor Retention. J Nucl Med. 2019 Oct;60(10):1421-1429.
[2]. Moon ES, et, al. Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA 5m chelators. EJNMMI Radiopharm Chem. 2020 Jul 29;5(1):19.

Reviews

Review for FAPI-46

Average Rating: 5 ★★★★★ (Based on Reviews and 33 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for FAPI-46

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.